Phase 2 prospective open label study of neoadjuvant nab‐paclitaxel, trastuzumab, and pertuzumab in patients with HER2‐positive primary breast cancer

BACKGROUND: The objective of this study was to evaluate the safety and efficacy of nab‐paclitaxel, trastuzumab, and pertuzumab as neoadjuvant therapy (NAT) in patients with human epidermal growth factor receptor 2 HER2+ breast cancer (HER2+ BC) to determine pathologic complete response (pCR), invasi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lavasani, Sayeh M., Somlo, George, Yost, Susan E., Frankel, Paul H., Ruel, Christopher, Cui, Yujie, Murga, Mireya, Tang, Aileen, Martinez, Norma, Kruper, Laura, Tumyan, Lusine, Schmolze, Daniel, Yeon, Christina, Yuan, Yuan, Waisman, James R., Mortimer, Joanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107275/
https://www.ncbi.nlm.nih.gov/pubmed/36517940
http://dx.doi.org/10.1002/cncr.34589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10107275/
https://www.ncbi.nlm.nih.gov/pubmed/36517940
http://dx.doi.org/10.1002/cncr.34589

Ejemplares similares